Allergan 3110-304-002: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Phase of Development: Phase III
Study Duration: 16 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Research Contact: 763-302-4162